Rapid Alert
| Spurious/Falsified Axtin Soft Gels (Batch # AXAF2301) |
| DRAP Alert No | No I/S/11-26-52 |
| Action Date | 12th November, 2026 |
| Target Audience | Regulatory Field Force of DRAP and Provincial Drug Control departments. Healthcare Professionals Consumers |
| Problem Statement | M/s Scotmann Pharmaceuticals (Health & OTC Division) (Nutraceuticals), 5-D, I-10/3 Industrial Area, Islamabad, the authorized manufacturer of Axtin Softgel, has reported the availability of a spurious therapeutic product in the market bearing a brand name and packaging similar to its duly enlisted product. The resemblance may mislead consumers and stakeholders regarding the authenticity of the product. Following are the details: |
| Sr. No. | Name of Product | Batch number | Name of Manufacturer | Remarks |
| 1 | Axtin Softgels | AXAF2301 | Axtin Healthcare Pvt. Ltd., plot no. 12, sector 6, IMT Manesar, Gurgaon, Haryana, India | The product is neither enlisted with DRAP nor manufactured, distributed, or endorsed by the authorized manufacturer, M/s Scotmann Pharmaceuticals (Health & OTC Division), Islamabad. |
| Risk Statement | The use of the above-mentioned Spuroiustherapeutic product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks. |
| Action Initiated | The Regulatory Field Force of DRAP and Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product. |
| Advice for Healthcare Professionals | DRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link. |
| Advice for Consumers | Consumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt. |